Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Poster presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2009. New Orleans, LA. [abstract] Blood. 2009 Nov 20; 114(22):2483. doi: 10.1182/blood.V114.22.2483.2483

Yong M, Schoonen WM, Li L, Kaye JA. A comparison of the sex-specific incidence of Immune thrombocytopenia in children, teenagers, and adults in the general practice research database. Poster presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 2009. New Orleans, LA. [abstract] Blood. 2009 Nov 20; 114(22):3502. doi: 10.1182/blood.V114.22.3502.3502

Dickson M, Stafkey-Mailey DR. The prevalence, mortality, and cost of central line blood stream infections (CLABSI) in US community hospitals: 2002-2006. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A431-2.

Candrilli SD, Balkrishnan R, O'Brien SH. Effect of injury severity on the incidence and utilization-related outcomes of venous thromboembolism in pediatric trauma inpatients. Pediatr Crit Care Med. 2009 Sep 1;10(5):554-7.

Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang OH, Rothman KJ. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in non-experimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep 1;54(3):554-60.

Ritchey ME, Jonsson Funk M, Marshall SW, Marinac-Dabic D, Rutala WA, Weber DJ. Changing rate of blood-stream infection across duration of central venous access. Poster presented at the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(S1).

Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.

Schoonen WM, Li L, Fryzek JP, Kaye JA. Medical contraindications for splenectomy among adults with immune thrombocytopenic purpura: data from the General Practice Research Database. Poster presented at 14th Congress of the European Hematology Association; June 4, 2009. Berlin, Germany. [abstract] Haematologica. 2009 Jun; 94(S2):96-7.

Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.

Mateus C, Wolowacz S, Pereira JA. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A148.

Earnshaw SR, Jackson DL, Farkouh RA, Schwamm LH. Cost-effectiveness of MRI-based selection of patients for intravenous thrombolysis. Stroke. 2009 Apr 1;40(4):E192-3.

Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, Fryzek J, Kaye JA. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol. 2009 Apr;145(2):235-44.

Knight C, Dano AM, Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia. 2009 Mar 1;15(2):405-19.

Leiss JK, Lyden JT, Mathews R, Sitzman KL, Vanderpuije A, Mav D, Kendra MA, Klein C, Humphrey CJ. Blood exposure incidence rates from the North Carolina study of home care and hospice nurses. Am J Ind Med. 2009 Feb 1;52(2):99-104.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan 1;101(1):77-85.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009 Jan 1;31(1):194-212.

Knight C, Dano AM, Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther. 2009 Jan 1;26(1):68-88.